Trial Profile
A Multi-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- Sponsors Novartis
- 09 Mar 2020 Results published in the British Journal of Cancer
- 16 Nov 2016 Status changed from active, no longer recruiting to completed.
- 21 Apr 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.